New stock news | Heng Intelligent will list on the Hong Kong Stock Exchange.
According to the disclosure by the Hong Kong Stock Exchange on February 9th, Huatai International and CMB International are the joint sponsors for Waihong Intelligent Technology Co., Ltd. (hereinafter referred to as "Waihong Intelligent") in its application for listing on the main board of the Hong Kong Stock Exchange.
According to the disclosure of the Hong Kong Stock Exchange on February 9th, Huatai International and CMB International are the joint sponsors for Heng Intelligent Technology Co., Ltd. (referred to as "Heng Intelligent") to submit its application for listing on the main board of the Hong Kong Stock Exchange. The prospectus reveals that Heng Intelligent is a leader in the digitalization of industrial and commercial energy storage solutions. According to Frost & Sullivan data, as of September 30, 2025, the company ranked eighth in the global industrial and commercial energy storage system shipments among 900 lithium-ion battery energy storage system integrators in China, and third in overseas markets. The company has always adhered to a global strategy and is one of the first Chinese companies to enter the overseas industrial and commercial energy storage market.
Related Articles
Pre-market report on A-shares | Stock exchange optimization of refinancing signals three major signals Rare earth product prices accelerate rise

Highlights of securities morning meeting | Insurance performance outlook for 2025: Full year profit and NBV are expected to continue high growth

INSILICO (03696) has reached collaboration agreements with CMS worth tens of millions of Hong Kong dollars in the research and development of multiple drugs in the central nervous system and autoimmune disease fields.
Pre-market report on A-shares | Stock exchange optimization of refinancing signals three major signals Rare earth product prices accelerate rise
Highlights of securities morning meeting | Insurance performance outlook for 2025: Full year profit and NBV are expected to continue high growth

INSILICO (03696) has reached collaboration agreements with CMS worth tens of millions of Hong Kong dollars in the research and development of multiple drugs in the central nervous system and autoimmune disease fields.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


